Create Medicines Acquisition | Healthcare Deal in MA

Create Medicines has completed the acquisition of Create Medicines, a healthcare services other business in Massachusetts, for $122 million. Create Medicines develops RNA-based in vivo CAR-T cell therapies that reprogram immune cells inside the body for cancer and autoimmune conditions. The company’s messenger RNA–lipid nanoparticle platform directs T cells, NK cells, and myeloid cells to self-reprogram, supporting a one-day manufacturing process that differs from traditional cell therapy workflows. The MA acquisitions financing is structured as a Series B to scale clinical programs, with Create reporting dosing of more than 50 patients and advancing MT-304, a HER2-targeted CAR therapy for HER2-positive breast cancer and other solid tumors. Healthcare M&A in MA is driven by the need for scalable in vivo CAR-T manufacturing and expanded immune-activation breadth, with co-leads including Arch Venture Partners, Newpath Partners, and Hatteras Venture Partners.